Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, but its stock sank more than 11% in trading despite the win.

Eli Lilly stock trades above all major moving averages, indicating a strongly bullish technical trend. Analysts see 3% upside, but momentum indicators suggest the rally could have more room to run.

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (NYSE ... Demand has been through the roof, and they generated a combined $16.5 ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Eli Lilly announced a successful ... Suffice it to say this would be a huge accomplishment for Lilly, expanding the addressable market for GLP-1 drugs (through ease of delivery, with no needles ...

However, a fact sheet issued by the White House suggests that the administration may pursue tariffs through Section 232 ... Tariffs Would Force Us To Pass Costs Directly To Consumers’ If ...

Eli Lilly Tuesday promoted its own LillyDirect platform, where patients can receive Zepbound through telehealth companies such as 9amHealth and FormHealth. Eli Lilly has also struck agreements ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for ...

according to which Wall Street analysts expect both companies to continue raising their dividend payments through 2027, but the Danish giant will do so at a faster rate [20% versus Eli Lilly's 12% ...

Let's figure out how Lilly could perform through the end of the decade, and decide whether it's still worth investing in the stock. First, let's consider how Eli Lilly's newest products will ...